about
Adjuvants for peptide-based cancer vaccinesCpG-based immunotherapy impairs antitumor activity of BRAF inhibitors in a B-cell-dependent mannerEffective innate and adaptive antimelanoma immunity through localized TLR7/8 activation.HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genesIntratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain.Induction of potent systemic anti-melanoma immunity through intratumoral CD40 activation and checkpoint blockade.Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy.Peptide Vaccine Formulation Controls the Duration of Antigen Presentation and Magnitude of Tumor-Specific CD8+ T Cell Response
P50
Q28072236-55C42C53-101C-4980-9838-AA8A737AA906Q33902560-B0AC453F-F443-4A64-AC80-711E309BF3E5Q34364876-BF9C5574-AFFD-4AE3-A648-7E4AA11237C0Q41633092-767A962B-B4D8-49E5-B19B-85C96166709EQ45854947-CCD4139B-FB90-43E4-AF1F-61EA12AC1522Q45907198-3A9C52FF-0968-488A-9C1D-55F7C941EAE4Q55386489-3CE40587-FAFB-44EC-9BAA-8BD35471616DQ88333970-10B096AE-FDC4-4801-B11D-8FC49CED3C76
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Hiep Khong
@ast
Hiep Khong
@en
Hiep Khong
@es
Hiep Khong
@nl
type
label
Hiep Khong
@ast
Hiep Khong
@en
Hiep Khong
@es
Hiep Khong
@nl
prefLabel
Hiep Khong
@ast
Hiep Khong
@en
Hiep Khong
@es
Hiep Khong
@nl
P106
P31
P496
0000-0003-4888-7862